AGM/EGMJun 22, 2026, 08:12 AM
SOPHiA GENETICS Names Ross Muken CEO, Dr. Camblong Executive Chairman
AI Summary
SOPHiA GENETICS announced that shareholders approved all proposals at its 2026 Annual General Meeting. Co-founder Dr. Jurgi Camblong was elected Executive Chairman of the Board, and Ross Muken was elected as a new Board member, set to become CEO on July 1, 2026. Shareholders also approved amendments to the Articles of Association, establishing a capital range from CHF 3.32 million to CHF 4.98 million and conditional capital provisions for employee participation and financing. Other approvals included compensation, financial statements, and the re-election of auditors.
Key Highlights
- Ross Muken appointed CEO, effective July 1, 2026.
- Co-founder Dr. Jurgi Camblong elected Executive Chairman of the Board.
- Shareholders approved all proposals at the 2026 Annual General Meeting.
- Approved capital range from CHF 3,319,908.20 to CHF 4,979,862.30.
- Conditional capital for employee participation up to CHF 1,240,378.20.
- Conditional capital for financing/acquisitions up to CHF 913,868.15.
- Approved maximum aggregate compensation for Board and Executive Committee.
- Re-elected PricewaterhouseCoopers SA as external auditors for 2026.
Price Impact
More from SOPH